Innate Pharma S.A. ADS share price logo

Innate Pharma S.A. ADS

NASDAQ: IPHA

Small Cap

$1.78

-0.01

(-0.56%)

as on

Innate Pharma S.A. ADS Stock Performance

as on June 18, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $1.75
    $1.81
    downward going graph

    1.69%

    Downside

    1.69%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $1.17
    $2.63
    downward going graph

    34.27%

    Downside

    47.75%

    Upside

    downward going graph

Innate Pharma S.A. ADS share price movements today

Previous Close
$1.79
Open
$1.75
Volume
215.9K
Day's Low - High
$1.75 - $1.81
52 Week Low - High
$1.17 - $2.63

Innate Pharma S.A. ADS Historical Returns

1 Month Return
-20.89 %
3 Month Return
+ 35.88 %
1 Year Return
-6.32 %
3 Year Return
-48.85 %
5 Year Return
-50.56 %

Innate Pharma S.A. ADS Stock Fundamentals & Key Indicators

Check Innate Pharma S.A. ADS market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$168.1M

EPS (TTM)

-0.5473

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.75%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-53.3M

Revenue (TTM)

9.0M

Profit Margin

0.00%

Return On Equity TTM

-271.37%

Innate Pharma S.A. ADS vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Innate Pharma S.A. ADS with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Innate Pharma S.A. ADS image
Innate Pharma S.A. ADS
BUY$168.1M-50.56%NA0.00%NA
Alnylam Pharmaceuticals Inc. image
Alnylam Pharmaceuticals Inc.
BUY$37.6B59.83%71.0112.55%NA
Vertex Pharmaceuticals Inc. image
Vertex Pharmaceuticals Inc.
BUY$115.0B144.34%26.8835.51%NA
Regeneron Pharmaceuticals Inc. image
Regeneron Pharmaceuticals Inc.
BUY$64.4B13.01%15.0229.65%0.58%

Stock Returns calculator for Innate Pharma S.A. ADS Stock including INR - Dollar returns

The Innate Pharma S.A. ADS stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Innate Pharma S.A. ADS investment value today

Current value as on today

₹1,02,565

Returns

₹2,565

(+2.57%)

Returns from Innate Pharma S.A. ADS Stock

-₹6,316 (-6.32%)

Dollar Impact

₹8,881 (+8.88%)

Analyst Recommendation on Innate Pharma S.A. ADS Stock

Based on 10 analysts

BUY

70.00%

Buy

30.00%

Hold

0.00%

Sell

Based on 10 analysts, 70% of analysts recommend a 'BUY' rating for Innate Pharma S.A. ADS. Average target price of $6

Innate Pharma S.A. ADS Share Price Target

Get share price movements and forecasts by analysts on Innate Pharma S.A. ADS.

What analysts predicted

70.33%UPSIDE

Target Price

$6

Current Price

$1.78

Analyzed by

10 Analysts

Target

$6.00

Innate Pharma S.A. ADS target price $6, a slight upside of 70.33% compared to current price of $1.78. According to 10 analysts rating.

Indian Investors' Interest in Innate Pharma S.A. ADS Stock

Search interest for Innate Pharma S.A. ADS Stock has increased by 683% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:683% versus previous 30 day period

Innate Pharma S.A. ADS Quarterly Profit & Loss

All numbers in Millions USD

Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Mar 2025
Jun 2025
Dec 2025
Mar 2026
Total Revenue
21
38
10
21
16
12
0
4
-2
-2
Gross Profit
4
21
-1
-3
-3
-16
29
-15
18
18
Operating Income
0
-5
-6
-12
-7
-26
-25
-25
-27
-27
EBITDA
1
0
-5
-10
-10
-25
-21
-25
-30
-30
Interest Expense
0
0
-
3
3
0
0
-
2
2
Depreciation
-
-
-
-
-
-
-
-
-
-
Income Before Tax
0
-3
-4
-9
-4
-24
-24
-21
-27
-27
Income Tax Expense
-3
-4
-
-9
-9
-
-
-
-2
-2
Net Income
0
1
-4
-9
-9
-24
-24
-21
-27
-27
Net Profit Margin
4.27%
4.86%
-43.31%
-43.31%
-56.10%
-200.60%
-8951.81%
-439.18%
1332.71%
1332.71%

Innate Pharma S.A. ADS Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
59
38
90
76
84
13
61
56
13
2
Gross Profit
7
-40
11
26
24
-25
6
6
13
2
Operating Income
7
-39
5
-27
1
-47
-57
-12
-51
-53
EBITDA
10
-35
-3
-20
13
-43
-12
-1
-46
-43
Interest Expense
0
0
0
0
0
0
0
0
0
0
Depreciation
-
4
7
16
56
4
45
5
1
5
Income Before Tax
12
-48
2
-20
0
-45
-57
-7
-49
-49
Income Tax Expense
0
0
0
0
6
13
41
-9
-
-5
Net Income
13
-57
3
-23
-77
-59
-61
-8
-51
-49
Net Profit Margin
22.51%
-148.28%
3.82%
-30.10%
-91.70%
-436.01%
-100.74%
-14.59%
-391.97%
-1764.51%

Innate Pharma S.A. ADS Quarterly Cash Flow

All numbers in Millions USD

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Mar 2025
Jun 2025
Dec 2025
Mar 2026
Net Income
1
-4
-9
-9
-24
-24
-23
-27
-27
Operating Cash Flow
-11
-10
-21
-21
3
-9
-34
-23
-23
Investing Cash Flow
0
-
-
20
0
8
7
0
0
Financing Cash Flow
-1
0
0
0
-4
-1
11
-3
-3
Change in Cash
-12
0
0
0
69
-3
-5
-25
-25

Innate Pharma S.A. ADS Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-48
3
-20
-63
-52
-58
-7
-49
-47
Operating Cash Flow
-48
-32
34
-51
-58
-19
-32
-6
-50
Investing Cash Flow
-29
24
-62
-13
0
1
20
9
7
Financing Cash Flow
0
61
77
-1
26
-1
-1
-6
5
Change in Cash
-76
52
50
-66
-33
-19
-13
-4
-30

Global Institutional Holdings in Innate Pharma S.A. ADS

Funds
Holdings
Exchange Traded Concepts, LLC
0%
Morgan Stanley - Brokerage Accounts
0.05%
UBS Group AG
0%
Optiver Holding B.V.
0%
Principal Securities Inc
0%
See all

Innate Pharma S.A. ADS News & Key Events

  • img

    Today's Timeline - 03 April

    Fri, 10:31 AM

    -

    Innate Pharma to hold one-on-one investor meetings at Kempen Life Sciences Conference on April 15-16, 2026.

Insights on Innate Pharma S.A. ADS

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Innate Pharma S.A. ADS has experienced a drawdown of -48.9%, however Alnylam Pharmaceuticals, Inc. Common Stock resisted the overall trend and outperformed by 26.5%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Regeneron Pharmaceuticals, Inc. Common Stock has given 18.4% return, outperforming this stock by 24.7%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 3 quarters, -21.34M → -27.62M (in $), with an average decrease of 14.7% per quarter

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 3 quarters, 4.86M → -2.07M (in $), with an average decrease of 71.3% per quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 month, IPHA stock has moved down by -20.9%

About Innate Pharma S.A. ADS

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.
OrganisationInnate Pharma S.A. ADS
Headquarters117, Avenue de Luminy, Marseille, France, 13009
IndustryBiotechnology
CEOMr. Jonathan E. Dickinson B.Sc., M.B.A.
E-voting on sharesClick here to vote

Key Management of Innate Pharma S.A. ADS

Name

Title

Ms. Stephanie Cornen

Vice President of Investor Relations, Communication & Commercial Strategy

Ms. Odile Belzunce

VP, Chief of Compliance & Operations Officer and Interim Head of HR

Mr. Jonathan E. Dickinson B.Sc., M.B.A.

CEO & Director

Mr. Jean Jacques Fournié Ph.D.

Founder

Mr. Frederic Lombard M.B.A.

Senior VP & CFO

Dr. Marc Bonneville Ph.D.

Founder

Mr. Alessandro Moretta M.D., Ph.D.

Founder

Mr. Yannis Morel Ph.D.

Executive VP & COO

Dr. Sonia Quaratino M.D., Ph.D.

Executive VP & Chief Medical Officer

Dr. François Romagné Ph.D.

Founder

FAQs

What is Innate Pharma S.A. ADS share price today?

Innate Pharma S.A. ADS share price today is $1.78 as on at the close of the market. Innate Pharma S.A. ADS share today touched a day high of $1.81 and a low of $1.75.

What is the 52 week high and 52 week low for Innate Pharma S.A. ADS share?

Innate Pharma S.A. ADS share touched a 52 week high of $2.63 on and a 52 week low of $1.17 on . Innate Pharma S.A. ADS stock price today i.e. is closed at $1.78,which is 32.32% down from its 52 week high and 52.14% up from its 52 week low.

What is Innate Pharma S.A. ADS's market capitalisation today?

Innate Pharma S.A. ADS market capitalisation is $0.00T as on .

How to invest in Innate Pharma S.A. ADS Stock (IPHA) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Innate Pharma S.A. ADS on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Innate Pharma S.A. ADS Shares that will get you 0.8427 shares as per Innate Pharma S.A. ADS share price of $1.78 per share as on June 18, 2026 at 8:45 am IST.

What is the minimum amount required to buy Innate Pharma S.A. ADS Stock (IPHA) from India?

Indian investors can start investing in Innate Pharma S.A. ADS (IPHA) shares with as little as ₹94.5 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹945.00 in Innate Pharma S.A. ADS stock (as per the Rupee-Dollar exchange rate as on ). Based on Innate Pharma S.A. ADS share’s latest price of $1.78 as on June 18, 2026 at 8:45 am IST, you will get 5.6180 shares of Innate Pharma S.A. ADS. Learn more about fractional shares .

What are the returns that Innate Pharma S.A. ADS has given to Indian investors in the last 5 years?

Innate Pharma S.A. ADS stock has given -50.56% share price returns and 27.67% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?